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Abstract
Background: Wnt-11 is a secreted protein that modulates cell growth, differentiation and morphogenesis during
development. We previously reported that Wnt-11 expression is elevated in hormone-independent prostate cancer
and that the progression of prostate cancer from androgen-dependent to androgen-independent proliferation
correlates with a loss of mutual inhibition between Wnt-11- and androgen receptor-dependent signals. However,
the prevalence of increased expression of Wnt-11 in patient tumours and the functions of Wnt-11 in prostate
cancer cells were not known.
Results: Wnt-11 protein levels in prostate tumours were determined by immunohistochemical analysis of prostate
tumour tissue arrays. Wnt-11 protein was elevated in 77/117 of tumours when compared with 27 benign prostatic
hypertrophy specimens and was present in 4/4 bone metastases. In addition, there was a positive correlation
between Wnt-11 expression and PSA levels above 10 ng/ml. Androgen-depleted LNCaP prostate cancer cells form
neurites and express genes associated with neuroendocrine-like differentiation (NED), a feature of prostate tumours
that have a poor prognosis. Since androgen-depletion increases expression of Wnt-11, we examined the role of
Wnt-11 in NED. Ectopic expression of Wnt-11 induced expression of NSE and ASCL1, which are markers of NED,
and this was prevented by inhibitors of cyclic AMP-dependent protein kinase, consistent with the known role of
this kinase in NED. In contrast, Wnt-11 did not induce NSE expression in RWPE-1 cells, which are derived from
benign prostate, suggesting that the role of Wnt-11 in NED is specific to prostate cancer. In addition, silencing of
Wnt-11 expression in androgen-depleted LNCaP cells prevented NED and resulted in apoptosis. Silencing of Wnt-
11 gene expression in androgen-independent PC3 cells also reduced expression of NSE and increased apoptosis.
Finally, silencing of Wnt-11 reduced PC3 cell migration and ectopic expression of Wnt-11 promoted LNCaP cell
invasion.
Conclusions: These observations suggest that the increased level of Wnt-11 found in prostate cancer contributes
to tumour progression by promoting NED, tumour cell survival and cell migration/invasion, and may provide an
opportunity for novel therapy in prostate cancer.
Background
Wnt genes code for secreted signalling proteins that are
responsible for the development and repair of many
organs in the body and aberrant activation of Wnt sig-
nalling is implicated in tumorigenesis [1]. We have pre-
viously reported increased expression of Wnt-11 mRNA
in androgen-independent prostate cancer (PCa) [2].
Wnt-11 is best known for its role during development,
for example, it is required for convergent extension
movements during gastrulation [3] and kidney morpho-
genesis [4]. In addition, cell-based assays have demon-
strated that Wnt-11 promotes cardiac differentiation [5],
increases proliferation, migration and transformation of
intestinal epithelial cells [6], reduces apoptosis in breast
cancer cells [7] and increases cell viability in chinese
hamster ovary (CHO) cells [8]. The signals downstream
of Wnt-11 are not fully characterised. Wnt-11 has been
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reported to inhibit JNK and NF-kappaB [8], activate
PKC and JNK [9] and activate cAMP response element
binding protein (CREB) family members [10]. Wnt-11
does not appear to stabilise b-catenin and is frequently
found to inhibit ‘canonical’ Wnt/b-catenin signalling
[2,8,11].
Despite its high level of expression in androgen-inde-
pendent PCa cells, ectopic expression of Wnt-11 inhibits
the growth of the androgen-dependent LNCaP cells [2].
The morphology of Wnt-11-transfected LNCaP cells
resembles that of androgen-depleted LNCaP cells as
they undergo neuroendocrine-like differentiation (NED)
[12], which we previously reported induces expression
of endogenous Wnt-11 [2]. This raised the possibility
that Wnt-11 may promote NED. Neuroendocrine (NE)
cells constitute a minor cell population in the normal
prostate that is thought to regulate prostatic growth and
differentiation. However, in prostate tumours, the num-
ber of NE-like cells correlates with tumour progression,
poor prognosis and the androgen-independent state
[12,13]. These and other observations have led to the
suggestion that PCa cells transdifferentiate to become
NE-like. Agents that induce NED elevate intracellular
levels of cyclic AMP (cAMP), and it has been postulated
that cAMP-mediated signalling is a primary pathway of
NED in vivo [14]. Here, we have further investigated the
function of Wnt-11 and show that it promotes NED in
a PKA-dependent manner and promotes prostate cancer
cell survival, migration and invasion.
Results
Increased expression of Wnt-11 in prostate tumours
In order to determine whether Wnt-11 protein levels are
elevated in patient tumours, we used anti-Wnt-11 anti-
bodies to localise Wnt-11 expression in sections taken
from human prostate and prostate tumour tissue (Figure
1). Benign prostate sections (27 cases) were either nega-
tive (not shown) or exhibited weak expression of Wnt-
11 in luminal epithelial cells and in some smooth mus-
cle cells (Figure 1a). Malignant prostate showed stronger
expression of Wnt-11 in luminal epithelial cells (Figures
1b, c). Immunohistochemical analysis of Wnt-11 in
tumour tissue arrays indicated that the level of Wnt-11
was elevated in 77/117 (66%) of tumours (Figures 1b -
1d), with particularly strong staining in 28/117 (24%) of
cases (Figure 1f). In addition, Wnt-11 was detected in 2/
2 examples of perineural invasion (Figure 1e) and in 4/4
bone metastases (Figure 1g, high expression of the
androgen receptor (AR) is shown in an adjacent section)
suggesting a possible role for Wnt-11 in invasion and/or
metastasis. Finally, Wnt-11 and AR were found to be
co-expressed in prostate tumour cells (Figures 1i, j). The
level of Wnt-11 expression was generally higher in PCa
compared to benign prostate. Analysis in relation to
conventional prognostic indices of PCa showed a nega-
tive correlation with Gleason grade; Wnt-11 was more
frequently found in Gleason 3 tumours than in Gleason
4 tumours and in Gleason < 8 compared to Gleason >
8, suggesting that Wnt-11 is not a general marker for
tumour dedifferentiation. However, Wnt-11 was signifi-
cantly elevated in tumours from patients with PSA levels
above 10 ng/ml (Table 1).
Wnt-11 promotes neuroendocrine-like differentiation in
prostate cancer cells
We noted that the morphology of Wnt-11-transfected
LNCaP cells resembled that of androgen-depleted
LNCaP cells as they undergo NED, raising the possibility
that Wnt-11 may be involved in NED. To test this pos-
sibility, we examined the effects of downregulation of
endogenous Wnt-11 in LNCaP cells. LNCaP cell lines
were generated expressing WNT11 shRNA or a non-
silencing control shRNA. RT-PCR analysis confirmed
upregulation of Wnt-11 upon hormone-depletion in
control shRNA cells but not in WNT11 shRNA cells
(Figure 2a). Culture of control shRNA cells in hormone-
depleted medium for a longer period of time resulted in
growth arrest and generation of neurite-like processes
(Figure 2b), as previously described for parental LNCaP
cells [15,16]. In contrast, hormone-depletion of WNT11
shRNA cells produced an initial morphological response
after one day in hormone-depleted medium (Figure 2b),
but thereafter the number of neuritic processes
decreased, with a significant reduction in the percentage
of cells with neurites after 4 days (Figure 2c). After 18
days in hormone-depleted medium, control shRNA cells
remained viable and had long neurites, whereas almost
all the WNT11 shRNA cells had died (Figure 2b).
To determine if the differences in neurite outgrowth
resulted from an inability of WNT11 shRNA cells to
undergo NED, extracts from cells cultured in hormone-
depleted medium were probed for a marker of NED,
neuron-specific enolase (NSE) (Figure 3a). Control
shRNA cells cultured in hormone-depleted medium
expressed NSE, whereas hormone-depleted WNT11
shRNA expressed very little NSE. Thus, endogenous
Wnt-11 appears to be required for expression of NSE, a
marker for NED, in hormone-depleted LNCaP cells.
Ectopic expression of Wnt-11 reduces proliferation of
LNCaP cells [2] and cell lines overexpressing Wnt-11
could be maintained for only a limited number of pas-
sages, suggesting that Wnt-11 induces LNCaP cell
growth arrest or differentiation. To determine whether
increased expression of Wnt-11 is sufficient to promote
NED, LNCaP cells were transfected with a Wnt-11
expression vector and the levels of expression of NSE and
a second gene, ASCL1, whose expression is increased
during NED [17] were measured (Figure 3b and
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Additional File 1). Wnt-11 increased expression of NSE
and ASCL1, suggesting that Wnt-11 is sufficient to
induce NED in LNCaP cells. Androgen depletion acti-
vates NED in LNCaP cells by increasing cellular levels of
cAMP, leading to activation of PKA [15]. Therefore we
tested the effect of inhibiting cAMP signalling on Wnt-
11 induction of these same genes. Wnt-11 induction of
NES and ASCL1 was reduced to baseline levels upon
treatment with four independent PKA inhibitors (H89,
KT5720, Rp-cAMPS and PKI, Figure 3c), suggesting that
Wnt-11 induction of NED requires activation of PKA.
NE-like differentiation is associated with a loss of AR
expression in both LNCaP cells and human tumours
[13]. Since Wnt-11 inhibits AR activity, we determined
whether ectopic expression of Wnt-11 in LNCaP cells
affected the expression level or localisation of AR. The
level of AR expression was reduced in LNCaP cells
expressing Wnt-11, but its subcellular localisation was
not affected (Figure 3d). This suggests that Wnt-11
induction of NE-like differentiation in LNCaP cells
might result from its ability to reduce AR expression.
However, LNCaP cells expressing Wnt-11 still expressed
some AR. In order to test whether Wnt-11 might also
play a role in NED in AR-negative PCa cells, we con-
ducted experiments using PC3 cells, an AR-negative,
PCa cell line that expresses high levels of Wnt-11 [2]
Figure 1 Wnt-11 protein expression in prostate and prostate cancer. Immunohistochemical analysis of Wnt-11 in (a) benign prostate; faint
cytoplasmic expression (black arrow) and stromal smooth muscle (red arrow) are indicated, (b-d) examples of Gleason 4 tumours, (e) Gleason 4
tumour with perineural invasion (inset arrowed), (f) a strongly positive Gleason 5 tumour, (g, h) adjacent sections of a prostate cancer bone
metastasis showing Wnt-11 (g) and androgen receptor (AR, h), and (i, j) adjacent sections of a Gleason 4 tumour showing Wnt-11 (i) and AR (j);
arrows show PCa cell co-expressing Wnt-11 and nuclear AR. Scale bar (a-f, i, j): 50 μm, (g, h, left to right): 200 μm, 75 μm and 25 μm.
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and displays some characteristics of NE cells [13]. It was
not possible to generate PC3 cell lines stably expressing
shRNAs and the transfection efficiency of the shRNA
vectors was too low to achieve silencing of WNT11.
Therefore, WNT11 was silenced by transient transfec-
tion of siRNA oligonucleotides. Silencing of WNT11 in
PC3 cells resulted in a reduction of NSE mRNA levels
24 h after transfection (Figure 3e). These results suggest
that Wnt-11 plays a role in NED of both AR-positive
and AR-negative prostate cancer cells. In order to deter-
mine if Wnt-11 was also involved in NED in untrans-
formed prostate epithelial cells, we expressed Wnt-11 in
RWPE-1 cells, which are derived from normal prostate
and exhibit features of prostate progenitor cells, includ-
ing the ability to differentiate into NE cells [18]. Expres-
sion of Wnt-11 did not affect the level of NSE mRNA in
RWPE-1 cells (Figure 3f). This difference did not result
from differences in the amount of Wnt-11 protein
expressed, since transfection efficiency was similar in
LNCaP and RWPE-1 cells (Additional File 2). This sug-
gests that Wnt-11 promotes NED in PCa cells but not
in untransformed prostate epithelial cells.
Silencing of WNT11 increases apoptosis in prostate
cancer cells
Silencing of WNT11 appeared to reduce the viability
of LNCaP cells grown in androgen-depleted medium
(Figure 2b). In order to determine if this reflected an
effect on apoptosis, cell extracts from androgen-depleted
control and WNT11 shRNA cells were probed for
cleaved PARP and cleaved caspase 9, which are fre-
quently used as indicators of apoptosis. The levels of
Table 1 Comparison of Wnt-11 protein expression and
tumour stage
Comparison
(Wnt-11 –ve versus Wnt-11 +ve)
p value
(Chi-squared test)
PSA < 10 ng/ml versus PSA > 10 ng/ml 0.0001
Gleason 4 versus Gleason 3 0.005
Gleason 5 versus Gleason 4 0.3
Gleason sum 7 versus Gleason sum 6 0.01
Gleason sum >8 versus Gleason sum <8 0.02
PNI +ve versus PNI -ve 0.6
Tumour samples from 117 patients were analysed. 77/117 (66%) of tumours
contained Wnt-11-positive epithelial cells, 28/117 (24%) of tumours were
strongly Wnt-11 positive and 4/4 bone metastases were Wnt-11 positive. Wnt-
11 expression correlated with increased serum PSA but lower Gleason score.
Statistical significance was determined using chi-squared test and results were
considered significant for p < 0.05. PSA, prostate-specific antigen; PNI,
perineural invasion.
Figure 2 Silencing of Wnt-11 reduces survival of androgen-depleted LNCP cells. (a) RT-PCR of WNT11 and GAPDH in LNCaP cell lines stably
expressing control (Ct) shRNA or WNT11 shRNA (clones 4 and 11) cultured for 7 days in hormone-depleted medium. (b) Images of control
shRNA or WNT11 shRNA (clone 11) LNCaP cells cultured for the indicated times in hormone-depleted medium. Scale bar 200 μm. Similar results
to those shown were obtained using three independent WNT11 shRNA clones. (c) Quantitation of neurite outgrowth of control shRNA or
WNT11 shRNA (clone 11) LNCaP cells cultured for 4 days in hormone-depleted medium. The data presented are the means (+/- SD) derived
from counting three fields of 100 cells; * p < 0.05.
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both cleaved proteins were elevated in androgen-
depleted WNT11 shRNA cells when compared to con-
trols (Figure 4a). Furthermore, caspase assays conducted
using extracts from WNT11 shRNA cells and control
shRNA cells grown in androgen-depleted medium con-
firmed that loss of Wnt-11 increases apoptosis in andro-
gen-depleted cells (Figure 4b). To determine whether
endogenous Wnt-11 also protected PC3 cells from
apoptosis, PC3 cells were transfected with control or
WNT11 siRNA oligonucleotides and then assayed for
caspase activity. Caspase activity was higher in WNT11
siRNA cells compared to in control cells (Figure 4c),
indicating that endogenous Wnt-11 also plays a role in
preventing apoptosis in this androgen-independent PCa
cell line.
Wnt-11 promotes prostate cancer cell migration and
invasion
Wnt-11 has been reported to affect migration during
development and in some cell lines [6,19,20]. To
Figure 3 Wnt-11 promotes neuroendocrine-like differentiation in PCa cells. (a) Extracts from control shRNA and WNT11 shRNA LNCaP cells
cultured for 3 days in hormone-depleted medium were probed by western blotting for neuron-specific enolase (NSE). The blot was then
stripped and re-probed for HSP60. (b) RT-PCR for WNT11, NSE, ASCL1 and GAPDH expression after transfection of LNCaP cells either with empty
vector (V) or Wnt-11 expression plasmid. (c) RT-PCR for NSE, ASCL1 and GAPDH expression levels in LNCaP cells transfected either with empty
vector (V, lane 1) or Wnt-11 expression plasmid (lanes 2-6) and cultured in the presence of carrier (DMSO, lanes 1 and 2), H89 (lane 3), KT5720
(lane 4) Rp-cAMPs (lane 5) or PKI (lane 6). (d) Immunostaining for Wnt-11 (red) and AR (green) in LNCaP cells transfected with Wnt-11 expression
plasmid. Red arrows indicate a cell with high Wnt-11 and low AR. TO-PRO-3 was used to stain nuclei. (e) RT-PCR for WNT11, NSE and GAPDH in
PC3 cells transfected with control siRNA (Ct si) or WNT11 siRNA (WNT11 si). (e) RT-PCR for WNT11, NSE and GAPDH in RWPE-1 cells transfected as
in (b) with empty vector (V) or Wnt-11 expression plasmid.
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determine if Wnt-11 was involved in PC-3 cell migra-
tion, cells were transfected with control or WNT11
siRNA oligonucleotides and assayed for their ability to
migrate through Transwell filters (Figure 5a). Compared
to the control siRNA, WNT11 siRNA reduced PC3 cell
transverse migration, suggesting that endogenous Wnt-
11 also plays a role in migration of this metastatic PCa
cell line. LNCaP cells, in contrast to PC3 cells, do not
migrate and are not normally invasive. However, LNCaP
cells can be induced to invade by secreted factors, for
example, neurotensin and components of FCS [21]. In
order to determine if Wnt-11 overexpression promotes
invasion, LNCaP cells were transfected with vector or
Wnt-11 expression plasmids and, after two days to
allow for Wnt-11 expression, plated on Matrigel-coated
filters in the presence of 1% FCS and invasion assays
performed. Expression of Wnt-11 increased the number
of invading LNCaP cells compared to control cells (Fig-
ure 5b). MTT assays indicated that there were no differ-
ences in the total numbers of cells during the assay
(data not shown). Together, these results indicate that
Wnt-11 not only plays roles in NED and survival of
prostate cancer cells, but also in their ability to migrate
and invade.
Discussion
Our results suggest that Wnt-11 can endow prostate
tumour cells with three properties important for PCa
progression, namely, increased resistance to apoptosis,
neuroendocrine-like differentiation and increased moti-
lity. The increased resistance to apoptosis provides a
survival mechanism for PCa cells not only under
Figure 4 Downregulation of Wnt-11 leads to apoptosis in prostate cancer cells. (a) Extracts from control shRNA and WNT11 shRNA LNCaP
cells grown in androgen-depleted medium for 7 days were probed by western blotting for cleaved PARP, cleaved caspase-9 and HSP60. (b)
Caspase assays from control shRNA and WNT11 shRNA LNCaP cells grown in androgen-depleted medium for 4 days. Caspase activity was
significantly higher in WNT11 shRNA cells (shaded bars) compared to in control shRNA cells (n = 6; p < 0.05). (c) Caspase assays from PC3 cells
transfected with control siRNA (white bars) or WNT11 siRNA (shaded bars). Caspase activity was significantly increased in WNT11 siRNA
transfected cells at 2 days and 3 days (n = 4; p < 0.001). All data are shown as means ± standard deviation.
Figure 5 Wnt-11 promotes prostate cancer cell migration and invasion. (a) PC3 cells were transfected for 72 hours with control or WNT11
siRNAs, plated on Transwell filters and the extent of migration determined. WNT11 siRNA decreased transverse migration (p = 0.02; n = 9).
Results are plotted as Migration Index (Mi), which is the percentage of migrated cells compared to the total number of cells seeded. (b) LNCaP
cells were transfected with empty vector or Wnt-11 expression plasmid, plated on Matrigel-coated transwell filters and the extent of invasion
determined. The extent of invasion was normalised to that in control cells (p = 0.01; n = 5). The total cell number did not change during the
course of the experiment.
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conditions of hormone-depletion but also in castrate-
resistant PCa. Wnt-11 has previously been shown to be
important for the survival and/or viability of MCF-7
breast cancer cells [7] and CHO cells [8], suggesting
that this is a general role for Wnt-11. It is not clear
whether the survival function of Wnt-11 in PCa is direct
or results from its effects on NED. WNT11 siRNA
reduced NSE expression in PC3 cells after 24 h, before
it significantly increased caspase activity (48 h), suggest-
ing that the principal role of Wnt-11 is to maintain
NED and that the inability to do this leads to apoptosis.
This would also be consistent with the known link
between NED and resistance to apoptosis [22]. Wnt-11
is known to play a role in differentiation in several tis-
sues, for example, promoting cardiomyogenic differen-
tiation of mesodermal cells [23], mouse embryonic stem
cells [24], endothelial circulating progenitor cells [25]
and bone marrow mononuclear cells [9], and this occurs
without effects on cell proliferation or survival in the
latter two examples. Nevertheless, Wnt-11 could play an
independent role in PCa cell survival and NED.
Wnt-11 inhibits AR transcriptional activity in LNCaP
cells and NED is associated with a loss of AR expression
[13]. Since ectopic expression of Wnt-11 in LNCaP cells
reduced the level of AR (Figure 3d), it is possible that
Wnt-11 induces NED indirectly by reducing AR expres-
sion. However, in contrast to what was observed in
LNCaP-derived NE-like cell lines, which express no AR
[13], expression of Wnt-11 did not lead to a complete
loss of AR. Moreover, Wnt-11 and AR are co-expressed
in other prostate cancer cell lines [2] and in prostate
tumour cells (Figure 1i, j). Wnt-11 induction of NED
was inhibited by four different inhibitors of PKA, sug-
gesting that Wnt-11 activates activate PKA to induce
NED. The signalling events that take place downstream
of Wnt-11 during NED are not known, but they may
involve activation of CREB, as observed during heart
morphogenesis [10], since CREB is activated upon
induction of NED and constitutively-active CREB can
itself induce NED [26].
The role of Wnt-11 in NED appears to be restricted
to PCa cells since ectopic expression of Wnt-11 did not
increase expression of NSE in non-tumorigenic RWPE-1
cells, even though these cells have the potential to
express this gene [18]. NE cells in the human prostate
are thought to originate from a stem/progenitor cell
that also gives rise to basal and secretory epithelial cells
[27]. They can be distinguished from most NE-like cells
derived from PCa cells because they are terminally dif-
ferentiated and do not co-express luminal epithelial cell
markers such as AR [13]. A recent study provided evi-
dence that cells initiating PCa are derived from a malig-
nantly transformed ‘intermediate’ cell that acquires stem
cell-like activity, rather than from a transformed normal
prostate stem cell [28]. If this holds true, Wnt-11 might
specifically promote NED of PCa cells but not of normal
progenitors, which could be important when considering
Wnt-11 as a potential target for therapy.
A role for Wnt-11 in cell migration was first suggested
by studies in Xenopus and zebrafish, where Wnt-11 pro-
motes convergent extension movements during gastrula-
tion [19,20]. More recently, Wnt-11 was shown to
promote migration of intestinal epithelial cells [6]. Our
demonstration that Wnt-11 is required for migration of
PC3 cells and promotes invasion of LNCaP cells (Figure 5)
underscores the potential of this molecule to promote PCa
metastasis. Consistent with this possibility, Wnt-11 was
detected in PCa cells in the process of invading the neural
sheath (Figure 1d) and in PCa bone metastases (Figure 1g).
The level of Wnt-11 expression was higher in PCa
compared to benign prostate but correlated inversely
with Gleason grade. This was unexpected given the high
level of expression of Wnt-11 in some high-grade
tumours (Figure 1f) as well as in all prostate tumour
bone metastases examined (Figure 1g and Table 1).
Wnt-11 may play a role in metastasis independent of
the state of differentiation or have different functions in
low grade and high-grade PCa. For example, in low-
grade PCa Wnt-11 might prevent apoptosis, whereas in
high-grade PCa it could promote invasion and, through
its effects on NED, promote progression to androgen-
independence. The relative importance of these roles at
each cancer stage and in each patient would likely
depend on other mutations present in the tumour.
Interestingly, there was a positive correlation between
Wnt-11 expression and patient PSA levels above 10 ng/
ml. This might seem at odds with the fact that Wnt-11
reduces AR activity in LNCaP cells. However, we pre-
viously showed that Wnt-11 does not inhibit AR activity
in androgen-independent AR-positive prostate cancer
cell lines [2]. Therefore it is possible that the Wnt-11-
positive tumours from patients with high PSA levels
contain an androgen-independent population of tumour
cells. A more detailed analysis using a larger cohort of
patients with follow-on data will be required to test
these possibilities.
Conclusions
This study shows that Wnt-11 protein levels are ele-
vated in a significant proportion of human prostate
tumours. In addition, it demonstrates that Wnt-11 is
both necessary and sufficient for induction of neuro-
endocrine-like differentiation in prostate cancer cells
and that this requires PKA activity. Finally, it shows that
Wnt-11 is required for prostate cancer cell survival and
promotes prostate cancer cell invasion. Taken together,
these observations suggest that Wnt-11 is a potential
therapeutic target in the treatment of prostate cancer.
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Methods
Cell culture
LNCaP, PC3 and RWPE-1 cells were from the American
Type Culture Collection (Rockville, MD, USA), pur-
chased through LGC Promochem. Cell stocks were fro-
zen within six months of receipt and, upon thawing,
used for up to six months. LNCaP and PC3 cells were
grown at 37°C, 5% CO2 in RPMI-1640 (Invitrogen) with
10% foetal bovine serum (FBS; First Link, UK) and anti-
biotics (100 units/mL penicillin, 100 μg/mL streptomy-
cin, Invitrogen, UK). RWPE-1 cells were grown in
Keratinocyte serum-free medium (KSFM) supplemented
with bovine pituitary extract and EGF (Invitrogen, UK).
LNCaP shRNA clones were grown in RPMI with 10%
tetracycline-free FBS (Clontech, Takara Bio USA). For
hormone-depletion experiments, LNCaP cells were cul-
tured in phenol red-free RPMI containing 5% charcoal-
stripped serum (CSS, First Link, UK). For transfections,
cells were cultured in Opti-MEM (Invitrogen). The fol-
lowing PKA inhibitors were used: H89 (10 μM, Calbio-
chem, UK), KT5720 (5 μM, Calbiochem, UK), Rp-
cAMPs (100 μM, Enzo Life Sciences, UK) and PKI (10
μM, Calbiochem, UK). Cells were incubated with inhibi-
tors for 24 h.
Plasmids, oligonucleotides and RT-PCR
A cDNA encoding human Wnt-11 (GeneCopoeia, Fre-
derick, MD) was subcloned into pcDNA3.1 (Invitrogen)
using EcoRI and XhoI. Plasmids expressing control and
WNT11 shRNAs were generated by ligation of annealed
oligonucleotides into pTER (21) with 5’ - 3’ sequences
as follows:
Control: GATCCCCTTCTCCGAACGTGTCACGTT-
TCAAGAGAACGTGACACGTTCGG
AGAATTTTTGGAAA
WNT11: GATCCCCGGACTCGGAACTCGTCTAT-
TTCAAGAGAATAGACGAGTTCCG
AGTCCTTTTTGGAAA
For RT-PCR, total RNA was extracted and analysed
according to manufacturer’s instructions (One step RT-
PCR, Qiagen, UK). The primer sequences (5’ - 3’) were:
WNT11 - CGATGCTCCTATGAAGGTGAAA,
CTTCCGTTGGATGTCTTGTTG
NSE - CTCATCAGCTCAGGTCTCTC, CCTTAC-
ACACGGCCAGAGAC
GAPDH - TGTTGCCATCAATGACCCCTT, CTCC-
ACGACGTACTCAGCG
The primers for ASCL1 were as previously described
[17]. The number of cycles used (32 for WNT11 and
NSE, 40 for ASCL1 and 22 for GAPDH) was determined
empirically so that there was a linear relationship
between target quantity and product yield to permit
semi-quantitative analysis. Analysis by real-time q-PCR
was done using iTaq SYBR Green premix (BIO-RAD)
and the following conditions: 95°C for 10 min, 40 cycles
at 95°C for 15 s, 60°C for 1 min and a dissociation stage
(95°C for 15 s, 60°C for 1 min, 95°C for 15 s, 60°C for
15 sec). GAPDH and ASCL1 primers used were as pre-
viously described [17]. Relative levels of mRNA expres-
sion were calculated using the Comparative CT Method,
2-ΔΔCT (ΔΔCT: ΔCT sample - ΔCT calibrator) [29].
Experiments were performed in triplicate and statistical
significance was analysed using Student’s t-Test, com-
paring ΔCT (CT target - CT housekeeping) obtained
from the calibrator.
Transfections
For Wnt-11 overexpression, LNCaP and RWPE-1 cells
were transiently transfected with pcDNA Wnt-11,
empty vector or pEGFP-C1 (Clontech) using Fugene-
HD (Roche) and assayed 48 h later. PKA inhibitors were
added 24 hours after transfection. To generate LNCaP
cell lines expressing control and WNT11 shRNAs,
LNCaP/TR2 cells [30] were transfected with pTER con-
trol shRNA or WNT11 shRNA plasmids using Tfx-50
(Promega), selected in medium containing 6 μg/ml blas-
ticidin and 300 μg/ml Zeocin (Invitrogen, UK) and colo-
nies then picked and expanded. WNT11 expression was
determined by RT-PCR analysis of clones cultured for 3
days in androgen-depleted medium. Three WNT11
shRNA clones with reduced expression of Wnt-11 and
three control shRNA clones were selected and used for
experiments. Experiments were conducted in medium
containing 5% CSS and doxycycline to induce expres-
sion of the shRNA. Despite the use of a Tet-inducible
LNCaP cell line and the pTER vector, expression of
WNT11 shRNA in the expanded clones was only weakly
affected by doxycycline (unpublished observations).
siRNA transfections were performed according to the
manufacturer’s protocols using DharmaFECT 2 (Dhar-
macon, USA). PC3 cells were seeded in 6-well plates for
48 h before transfection using ON-TARGETplus
SMARTpool WNT11 siRNA or ON-TARGETplus non-
targeting pool (Dharmacon, USA). Transfected cells
were processed for RNA extraction (after 24 and 48 h)
or caspase activity (after 24, 48 and 72 h) or used in cell
migration assays (72 h).
Antibodies, western blotting and immunostaining
The following antibodies were used: mouse anti-NSE
(BBS/NC/V1-H14, Dako), rabbit anti-cleaved caspase-9
(Asp330; 9501) and rabbit anti-cleaved PARP (Asp214;
9541) (both from Cell Signalling Technology), rabbit
anti-AR (N20; sc-816, Santa Cruz Biotechnology),
mouse anti-HSP60 (SPA-806, Stressgen) and goat anti-
Wnt-11 (R&D systems, AF2647). Rabbit anti-Wnt-11
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(H-95; sc-50360, Santa Cruz Biotechnology) was also
used for immunohistochemistry to confirm the results
using goat anti-Wnt-11. For immunocytochemistry,
transfected RWPE-1 and LNCaP cells were fixed in 4%
paraformaldehyde for 15 min, blocked with 5% BSA/PBS
for 30 min and incubated with rabbit anti-Wnt-11 (1:20)
and/or mouse anti-AR (clone AR441, Dako, 1:40) over-
night at 4°C. Alexa Fluor® 488 goat anti-mouse IgG
(H+L) and/or Alexa Fluor® 555 goat anti-rabbit IgG
(H+L) (Invitrogen) were used as secondary antibodies
(1:500, 60 min at room temperature) and nuclei were
counterstained using 1.0 μM TO-PRO-3 (Invitrogen).
Images were acquired on a LSM 510 laser scanning con-
focal microscope (Carl Zeiss). Preparation of extracts and
western blotting were done as previously described (23).
Blots were stripped and re-probed for HSP60 to control
for gel loading. Human Prostate cancer and adjacent nor-
mal prostate tissues (tissue arrays and single tissue slides)
were purchased from SuperBioChips Laboratories (single
slides and TMA-CA3), Stretton Scientific (TMA-A222)
and US BioMax Inc. (TMA-PR951). Samples were pro-
vided as formalin-fixed, paraffin-embedded and sectioned
for histological analysis. Representative haematoxylin-
eosin-stained sections were examined to evaluate the his-
topathological characteristics of the lesion to be analysed.
The suppliers provided patient pathology data, when
available. All samples were independently analysed for
Gleason grade by a pathologist (MMW). Sections were
deparaffinised and rehydrated using graded alcohol con-
centrations. Antigen retrieval was performed by incuba-
tion in 10 mM sodium citrate pH 6.0 and heating in a
microwave oven at 560 W for 8 min. Endogenous peroxi-
dase was quenched using 3% H2O2 for 30 min. Following
blocking (30 min in PBS with 1.5% horse serum), sections
were incubated with goat anti-Wnt-11 at 1:200, rabbit
anti-Wnt-11 at 1:50 or anti-AR at 1:200 for 1 h at room
temperature. Washing and antibody visualisation was
done using the Vectastain Elite ABC Standard kit accord-
ing to manufacturer’s instructions (Vector Labs). TMA
analysis was performed using an image analyser (Chro-
maVision ACIS II, Zeiss, Germany). Tissue samples were
scored by MMW for Wnt-11 levels in prostate cancer
epithelial cells (0 = no signal; 1 = positive, and 2 =
strongly positive).
Assays for morphology, apoptosis, cell number, migration
and invasion
For morphological analysis, images of live cells were
taken and analysed using ImageJ software http://rsb.info.
nih.gov/ij. The numbers of cells with and without neur-
ites longer than two cell bodies were counted in photo-
micrographs of control and WNT11 shRNA cells that
had been cultured for 4 days in hormone-depleted med-
ium. The data presented are the means derived from
counting three fields of 100 cells from a representative
experiment (n = 2). For caspase assays, trypsinised cells
were plated at a density of 5000 cells per well in opaque
96-well cell culture plates (Perkin Elmer). At the indi-
cated times after plating, an equal volume of Caspase-
Glo 3/7 reagent (Promega) was added, the plate was
incubated for 30 min and readings were taken using a
luminometer. To normalise for cell number, MTT
assays were conducted in parallel using the same num-
ber of cells plated in normal 96-well tissue culture
plates. The number of viable cells was measured by add-
ing 200 μl sterile MTT (3- [4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide, 5 mg/ml) diluted in
fresh medium to each well, loosely wrapping the plate
in foil and incubating at 37°C for 3 h. The media were
then replaced with 250 μl DMSO, followed by 25 μl gly-
cine buffer (0.1 M glycine, 0.1 M NaCl, pH 10.5) and
absorbance at 570 nm was read within 10 min. Details
of PC3 cell migration assays were as described pre-
viously (24). Briefly, cells were trypsinised and plated at
2 × 104 cells/well onto 12-micron pore Transwell filters
with a polycarbonate membrane (Corning). Following 6
h incubation, the MTT assays were used to determine
the number of migrated cells and the results were
plotted as Migration Index (Mi), which is the percentage
of migrated cells compared to the total number of cells
seeded. MTT assays were used to confirm that that
there was no effect on total cell number during the 6 h
time course of the experiments. LNCaP invasion assays
were done in similar manner to Vias et al. [21], except
that LNCaP cells were first transfected with vector or
Wnt-11 plasmid and, after 48 hours, 5 × 105 transfected
cells were plated on Matrigel-coated Transwell filters
(BD Biosciences) in growth medium containing 1% FCS
or 1% CSS supplemented with DHT to prevent expres-
sion of endogenous Wnt-11 (both conditions gave simi-
lar results). After a further 42 h, the number of invaded
cells was determined by MTT assay. The total number
of cells plated was also determined by MTT assay.
Data analysis
All data were analysed as means ± standard deviation.
Statistical significance was determined using Student’s
t-test or chi-squared test, as appropriate; results were
considered significant for p < 0.05.
Additional file 1: q-PCR analysis of ASCL1 expression. Expression of
ASCL1 (relative to GAPDH) in LNCaP cells transfected with vector
(Control) or Wnt-11 expression plasmid or cultured in hormone-depleted
medium (CSS). Values are means +/- SD from three independent
experiments, normalised to control. ASCL1 expression was significantly
higher in Wnt-11-transfected cells than in control-transfected cells (p =
0.04).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1476-4598-9-55-
S1.TIFF ]
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Additional file 2: Comparison of transfection efficiency of LNCaP
and RWPE-1 cells. (a, b) Images of LNCaP (a) and RWPE-1 (b) cells
transfected for 48 h with GFP plasmid. GFP is shown in green and cell
nuclei in blue. A similar proportion of cells (5%) expressed GFP in both
cell lines. (c, d) LNCaP (c) and RWPE-1 (d) were transfected with Wnt-11
plasmid and, after 48 h, stained for Wnt-11 (red). Wnt-11 staining was of
a similar intensity in both cell lines.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1476-4598-9-55-
S2.TIFF ]
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